The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | TRIMM-2: talquetamab + daratumumab in patients with R/R multiple myeloma
Bhagirathbhai Dholaria, MBBS, Vanderbilt University Medical Center, Nashville, TN, comments on the updated results from the TRIMM-2 study (NCT04108195), which is evaluating daratumumab in combination with various bispecific antibodies in patients with relapsed/refractory (R/R) multiple myeloma. In this video, Dr Dholaria discusses the results of patients treated with daratumumab and talquetamab, highlighting the overall response rate (ORR), very good partial response (VGPR) and durability of responses observed. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
